XBiotech Inc (XBIT) - Net Assets
Based on the latest financial reports, XBiotech Inc (XBIT) has net assets worth $140.35 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($150.08 Million) and total liabilities ($9.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check XBIT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $140.35 Million |
| % of Total Assets | 93.52% |
| Annual Growth Rate | 25.44% |
| 5-Year Change | -47.9% |
| 10-Year Change | 137.62% |
| Growth Volatility | 470.42 |
XBiotech Inc - Net Assets Trend (2012–2025)
This chart illustrates how XBiotech Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of XBiotech Inc.
Annual Net Assets for XBiotech Inc (2012–2025)
The table below shows the annual net assets of XBiotech Inc from 2012 to 2025. Also explore net asset growth rate of XBiotech Inc to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $140.35 Million | -23.00% |
| 2024-12-31 | $182.27 Million | -16.71% |
| 2023-12-31 | $218.85 Million | -8.97% |
| 2022-12-31 | $240.40 Million | -10.76% |
| 2021-12-31 | $269.38 Million | -22.73% |
| 2020-12-31 | $348.64 Million | -53.86% |
| 2019-12-31 | $755.63 Million | +1725.28% |
| 2018-12-31 | $41.40 Million | -31.19% |
| 2017-12-31 | $60.16 Million | +1.86% |
| 2016-12-31 | $59.06 Million | -42.68% |
| 2015-12-31 | $103.05 Million | +74.57% |
| 2014-12-31 | $59.03 Million | +477.14% |
| 2013-12-31 | $10.23 Million | +38.74% |
| 2012-12-31 | $7.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to XBiotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7486000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $276.73 Million | 197.17% |
| Total Equity | $140.35 Million | 100.00% |
XBiotech Inc Competitors by Market Cap
The table below lists competitors of XBiotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Quality Houses Hotel and Residence Freehold and Leasehold Property Fund
BK:QHHR
|
$66.50 Million |
|
Apex Science & Engineering Corp
TW:3052
|
$66.52 Million |
|
Camus Engineering & Construction Inc
KO:013700
|
$66.57 Million |
|
Decidr Ai Industries Ltd
AU:DAI
|
$66.57 Million |
|
BitNine Co. Ltd.
KQ:357880
|
$66.44 Million |
|
Interlink Electronics Inc
NASDAQ:LINK
|
$66.44 Million |
|
Cypherpunk Technologies Inc.
NASDAQ:CYPH
|
$66.42 Million |
|
Tsann Kuen Enterprise Co Ltd
TW:2430
|
$66.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XBiotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 182,268,000 to 140,350,000, a change of -41,918,000 (-23.0%).
- Net loss of 45,540,000 reduced equity.
- Other factors increased equity by 3,622,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-45.54 Million | -32.45% |
| Other Changes | $3.62 Million | +2.58% |
| Total Change | $- | -23.00% |
Book Value vs Market Value Analysis
This analysis compares XBiotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.47x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 9.38x to 0.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.23 | $2.18 | x |
| 2013-12-31 | $0.32 | $2.18 | x |
| 2014-12-31 | $1.86 | $2.18 | x |
| 2015-12-31 | $3.35 | $2.18 | x |
| 2016-12-31 | $1.82 | $2.18 | x |
| 2017-12-31 | $1.73 | $2.18 | x |
| 2018-12-31 | $1.16 | $2.18 | x |
| 2019-12-31 | $16.31 | $2.18 | x |
| 2020-12-31 | $11.31 | $2.18 | x |
| 2021-12-31 | $8.97 | $2.18 | x |
| 2022-12-31 | $7.90 | $2.18 | x |
| 2023-12-31 | $7.19 | $2.18 | x |
| 2024-12-31 | $5.98 | $2.18 | x |
| 2025-12-31 | $4.60 | $2.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XBiotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-32.45%) is above the historical average (-40.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -205.64% | 0.00% | 0.00x | 1.15x | $-15.90 Million |
| 2013 | -97.06% | 0.00% | 0.00x | 1.08x | $-10.95 Million |
| 2014 | -36.80% | 0.00% | 0.00x | 1.05x | $-27.63 Million |
| 2015 | -36.37% | 0.00% | 0.00x | 1.06x | $-47.79 Million |
| 2016 | -89.33% | 0.00% | 0.00x | 1.14x | $-58.67 Million |
| 2017 | -55.10% | 0.00% | 0.00x | 1.05x | $-39.17 Million |
| 2018 | -51.06% | 0.00% | 0.00x | 1.07x | $-25.28 Million |
| 2019 | 88.49% | 5272.68% | 0.02x | 1.08x | $593.07 Million |
| 2020 | -3.22% | -25.50% | 0.12x | 1.01x | $-46.08 Million |
| 2021 | -6.46% | -94.67% | 0.07x | 1.02x | $-44.35 Million |
| 2022 | -13.69% | -820.45% | 0.02x | 1.02x | $-56.94 Million |
| 2023 | -11.22% | -8185.67% | 0.00x | 1.04x | $-46.44 Million |
| 2024 | -21.14% | 0.00% | 0.00x | 1.09x | $-56.76 Million |
| 2025 | -32.45% | 0.00% | 0.00x | 1.07x | $-59.58 Million |
Industry Comparison
This section compares XBiotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XBiotech Inc (XBIT) | $140.35 Million | -205.64% | 0.07x | $66.46 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown… Read more